Oligometastatic NSCLC: Current Perspectives and Future Challenges

Oligometastatic NSCLC: Current Perspectives and Future Challenges

Oligometastatic non-small cell lung cancer (NSCLC) represents a separate entity with a different biology and prognosis compared to stage IV NSCLC. Challenges range from the very definition of oligometastatic disease to the timing and techniques of local treatments, and their benefit in prolonging pa...

Full description

Saved in:

Bibliographic Details
Main Authors:	Sara Torresan, Jacopo Costa, Carol Zanchetta, Lorenzo De Marchi, Simona Rizzato, Francesco Cortiula
Format:	Article
Language:	English
Published:	MDPI AG 2025-01-01
Series:	Current Oncology
Subjects:	NSCLC oligometastatic oligoprogressive oncogene-addicted NSCLC non-oncogene-addicted NSCLC
Online Access:	https://www.mdpi.com/1718-7729/32/2/75
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Prognostic and Predictive Biomarkers of Oligometastatic NSCLC: New Insights and Clinical Applications
by: Mandy Jongbloed, MD, et al.
Published: (2024-12-01)

Early local therapy in combination with PD-1/PD-L1 inhibitors in oligometastatic non-small cell lung cancer: results from a prospective multicenter observational study
by: Jie Gao, et al.
Published: (2025-03-01)

Evaluation of the optimal timing of radiotherapy in EGFR-Mutant oligometastatic NSCLC through a retrospective analysis of treatment sequences and survival outcomes
by: Meng Zhang, et al.
Published: (2025-08-01)

Impact of Immune Checkpoint Inhibitors and Local Radical Treatment on Survival Outcomes in Synchronous Oligometastatic NSCLC
by: Mandy Jongbloed, MD, et al.
Published: (2025-03-01)

The role of radiotherapy in the treatment of oligometastatic non-small cell lung cancer
by: Radovan Vojtišek
Published: (2025-01-01)

Effectiveness and Safety of Systemic Therapy and Stereotactic Body Radiotherapy in Oligoprogressive and Oligometastatic Hepatocellular Carcinoma
by: Song Z, et al.
Published: (2025-05-01)

Symptomatic Bradycardia Due to Alectinib in a Patient with Advanced Stage of NSCLC
by: Ceva Wicaksono Pitoyo, et al.
Published: (2022-07-01)

Prognostic impact of body composition and immune-nutritional status in oligometastatic NSCLC patients receiving radiotherapy
by: Zhifei Huang, et al.
Published: (2025-07-01)

A Phase 1/1B Trial of Pembrolizumab and Trametinib in Advanced NSCLC Enriched for KRAS Mutations
by: Jonathan W. Riess, MD, MS, et al.
Published: (2025-06-01)

A Real‐World Study: Therapeutic Outcomes of ROS1‐Positive Advanced NSCLC
by: Hanqi Yuan, et al.
Published: (2025-05-01)

Spatial heterogeneity of T cell repertoire across NSCLC tumors, tumor edges, adjacent and distant lung tissues
by: Qikang Hu, et al.
Published: (2023-12-01)

The Effects of Silibinin Combined With EGFR‐TKIs in the Treatment of NSCLC
by: Xiaocen Wang
Published: (2025-02-01)

Occult Node Detection With Lobectomy Versus Segmentectomy for Stage IA NSCLC
by: Yota Suzuki, MD, et al.
Published: (2025-08-01)

A novel radiomics model combining GTVp, GTVnd, and clinical data for chemoradiotherapy response prediction in patients with advanced NSCLC
by: Ya Li, et al.
Published: (2025-07-01)

Responsive afatinib treatment in high-grade salivary gland ductal carcinoma and NSCLC with uncommon EGFR mutations: Treatment outcomes
by: Sivakamavalli Jeyachandran
Published: (2024-06-01)

Phase 2 Trial of Combination Radiotherapy and Pembrolizumab Plus Chemotherapy in Patients With Previously Untreated Metastatic NSCLC: NJLCG 1902
by: Yoko Tsukita, MD, PhD, et al.
Published: (2025-05-01)

PD-1/PD-L1 blockade therapy with atezolizumab: a new paradigm in the treatment of non-small cell lung cancer (NSCLC)
by: Samaneh Moradi, et al.
Published: (2025-03-01)

CANOPY-N: A Phase 2 Study of Canakinumab or Pembrolizumab, Alone or in Combination, as Neoadjuvant Therapy in Patients With Resectable, Stage IB–IIIA NSCLC
by: Jay M. Lee, MD, et al.
Published: (2025-08-01)

Identification of exosome-related genes in NSCLC via integrated bioinformatics and machine learning analysis
by: Zhenjie Sun, et al.
Published: (2025-07-01)

AJUBA promotes the proliferation, invasion and migration of NSCLC cells by activating the ERK/β-catenin pathway
by: Lianyue Qu, et al.
Published: (2025-04-01)

STUDI IN SILICO KOMPLEKS LIGAND-RESEPTOR EUGENOL DAUN BASIL (Ocimum basilicum L.) DENGAN RESEPTOR HER2 PADA NON-SMALL CELL LUNG CANCER (NSCLC) DENGAN KONTROL GEFITINIB
by: Martina Kurnia Rohmah
Published: (2017-09-01)

Cudratricusxanthone A exhibits antitumor activity and enhances chemosensitivity to cisplatin against NSCLC via targeting EGFR
by: Peiyuan Sun, et al.
Published: (2025-08-01)

Efficacy and safety analysis of lorlatinib for ALK-positive advanced NSCLC: a multicentre real-world study in China
by: Zhujun Chen, et al.
Published: (2025-07-01)

Advancing EGFR mutation subtypes prediction in NSCLC by combining 3D pretrained ConvNeXt, radiomics, and clinical features
by: Peng Hao, et al.
Published: (2024-11-01)

Osimertinib plus chemotherapy versus osimertinib for patients with advanced NSCLC with concomitant EGFR and TP53 mutations: a prospective cohort study
by: Jixian Li, et al.
Published: (2025-07-01)

The Role of Eosinophils, Eosinophil-Related Cytokines and AI in Predicting Immunotherapy Efficacy in NSCLC
by: Fausto Omero, et al.
Published: (2025-03-01)

Intracellular cholesterol: new functions and therapeutic approaches in NSCLC EGFR-TKI resistance
by: Linjuan Wang, et al.
Published: (2025-07-01)

Identification of a Biomarker Panel in Extracellular Vesicles Derived From Non‐Small Cell Lung Cancer (NSCLC) Through Proteomic Analysis and Machine Learning
by: Ye Yuan, et al.
Published: (2025-05-01)

Metabolically activated and highly polyfunctional intratumoral VISTA+ regulatory B cells are associated with tumor recurrence in early-stage NSCLC
by: Domenico Lo Tartaro, et al.
Published: (2025-01-01)

TRANS: a prediction model for EGFR mutation status in NSCLC based on radiomics and clinical features
by: Zhigang Chen, et al.
Published: (2025-06-01)

Clinical Management in NSCLC Patients With EGFR Mutation After Osimertinib Progression With Unknown Resistance Mechanisms
by: Xin Liao, et al.
Published: (2024-10-01)

Update on Practical Management of Early-Stage Non-Small Cell Lung Cancer (NSCLC): A Report from the Ontario Forum
by: Parneet K. Cheema, et al.
Published: (2024-11-01)

Long-Term Oncological Outcomes Related to Lymphadenectomy in Clinical Stage I NSCLC: A Multicenter Retrospective Experience
by: Beatrice Manfredini, et al.
Published: (2025-01-01)

Identifying key genes associated with recurrence in non-small cell lung cancer through TCGA and single-cell analysis
by: Weiyuan Li, et al.
Published: (2025-06-01)

Perioperative Chemo/Immunotherapies in Lung Cancer: A Critical Review on the Value of Perioperative Sequences
by: Thoma’ Dario Clementi, et al.
Published: (2025-07-01)

Case Report: Pathologic complete response in a patient with simultaneous diagnoses of resectable NSCLC and myeloid neoplasm with PDGFRA rearrangement treated with concurrent neoadjuvant chemoimmunotherapy and imatinib: translating clinical trial data to real-world practice
by: Chad B. Sussman, et al.
Published: (2025-07-01)

EGFR-mediated local invasiveness and response to Cetuximab in head and neck cancer
by: Jiefu Zhou, et al.
Published: (2025-03-01)

Tertiary lymphoid structure-related immune infiltrates in NSCLC tumor lesions correlate with low tumor-reactivity of TIL products
by: Suzanne M. Castenmiller, et al.
Published: (2024-12-01)

Peripheral memory B cell population maintenance and long-term survival after perioperative chemoimmunotherapy in NSCLC (NADIM trial)
by: Belén Sierra Rodero, et al.
Published: (2025-12-01)

Comparison of first-generation EGFR-TKIs combined with low-dose bevacizumab versus osimertinib in untreated advanced EGFR-mutated NSCLC
by: Yingqi Xu, et al.
Published: (2025-12-01)